-
公开(公告)号：US11718661B2
公开(公告)日：2023-08-08
申请号：US17288013
申请日：2019-10-29
Applicant: INSERM (Institut National de la Santé et de la Recherche Médicale) , Sorbonne Université , Assistance Publique-Hôpitaux de Paris (APHP)
Inventor： Guy Gorochov , Martin Larsen , Delphine Sterlin , Jehane Fadlallah
CPC classification number: C07K16/1271 , A61K9/0053 , A61P1/00 , A61P37/04 , A61K2039/505 , A61K2039/542 , C07K2317/33
Abstract: The invention is in the field of therapy of antibody deficiencies. Inventors demonstrate for the first time in both controls and IgA-deficient patients, systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Furthermore, SIgAd-associated inflammation is inversely correlated with systemic anti-commensal IgG responses, which may thus serve as a second line of defense. Altogether, these data suggest that systemic IgG and intestinal IgA cooperate in different body compartments to limit systemic pro-inflammatory pathways. As selective IgA deficient patients harbour elevated seric anti-commensal IgG levels, these findings suggest that in selective IgA deficiency, microbiota confinement is obtained at the price of a strong inflammatory response. Accordingly, the invention relates to a composition containing immunoglobulins A (IgA), more particularly secretory IgA, for use by oral administration in the prevention or treatment of antibody deficiencies such as SIgAd (Selective IgA deficiency) or common variable immunodeficiency (CVID) and associated inflammatory diseases.
-
公开(公告)号：US20230235408A1
公开(公告)日：2023-07-27
申请号：US18003535
申请日：2021-06-28
Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) , SORBONNE UNIVERSITÉ , UNIVERSITÉ DE PARIS
Inventor： Franck PAGES , Jérôme GALON , Guy ZEITOUN , Amos KIRILOVSKY
IPC: C12Q1/6886 , G01N33/574 , G01N33/569
CPC classification number: C12Q1/6886 , G01N33/57419 , G01N33/56972 , G01N2800/52 , C12Q1/6869
Abstract: The inventors assessed in locally advanced rectal cancer whether a diagnostic biopsy-adapted Immunoscore (ISg) could predict response to neoadjuvant treatment (nT) and better define patients eligible to an organ preservation strategy (“Watch-and-Wait”). The inventors showed that ISB was an independent parameter, more informative than pre- (P
-
公开(公告)号：US20230190965A1
公开(公告)日：2023-06-22
申请号：US18049296
申请日：2022-10-25
Applicant: GENETHON , UNIVERSITE D'EVRY VAL D'ESSONNE , INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , SORBONNE UNIVERSITÉ
Inventor： FEDERICO MINGOZZI , GIUSEPPE RONZITTI , PATRICE VIDAL
CPC classification number: A61K48/0066 , A61K48/0033 , A61P3/08 , C12N7/00 , C12N9/16 , C12Y301/03001 , C12N2750/14121 , C12N2750/14132 , C12N2750/14143 , C12N2750/14145
Abstract: The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.
-
公开(公告)号：US20230183187A1
公开(公告)日：2023-06-15
申请号：US17998436
申请日：2021-05-12
Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , COMMISSARIAT À L'ÉNERGIE ATOIMQUE ET AUX ÉNERGIES ALERNATIVES , UNIVERSITE PARIS-SACLAY , SORBONNE UNIVERSITÉ , ASSOCIATION FRANÇAISE CONTRE LES MYOPATHIES , ASSOCIATION INSTITUT DE MYOLOGIE
Inventor： Olivier NAMY , Laure BIDOU , Olivier BUGARD , Jean-Christophe CINTRAT , Goulven MERER , Egor CHIRKIN
IPC: C07D239/84
CPC classification number: C07D239/84
Abstract: The present invention relates to the use of at least one compound of formula (I), or one of its pharmaceutically acceptable salts, for preventing and/or treating a disease caused by a nonsense mutation. It also relates to compounds of formula (II) and their uses.
-
15.发明公开公开(公告)号：US20230159609A1
公开(公告)日：2023-05-25
申请号：US17995880
申请日：2020-07-10
Applicant: Sorbonne Université , Centre National de la Recherche Scientifique , INSERM (Institut National de la Santé et de la Recherche Médicale) , Ruhr-Universität Bochum , Centrre Hospitalier National d'Ophtalmologie Quinze-Vingts
Inventor： Deniz DALKARA , Cardillia-Joe SIMON , Stefan HERLITZE , José-Alain SAHEL , Isabelle AUDO , Serge PICAUD , Stéphane Bertin
IPC: C07K14/705 , C12N15/86 , C07K14/005 , A61P27/02 , A61P25/00
CPC classification number: C07K14/705 , C12N15/86 , C07K14/005 , A61P27/02 , A61P25/00 , C12N2750/14143 , C12N2750/14145 , C12N2750/14171 , C12N2750/14122 , A61K48/00
Abstract: The present invention concerns a new gene therapy approach to increase light-sensitivity in degenerating cones in advanced stages of rod-cone dystrophy (RCD) mediated by G-protein-gated-K+ channel (GIRK), in particular GIRK2, activated by G proteins recruited by cone opsin expressed in degenerating cones.
-
Patent Agency Ranking
16.发明公开公开(公告)号：US20230151425A1
公开(公告)日：2023-05-18
申请号：US17905899
申请日：2021-03-10
Applicant: INSERM (Institut National de la Santé et de la Recherche Médicale) , Sorbonne Université , Université Paris Cité , Assistance Publique-Hôpitaux de Paris , Fondation Asile des Aveugles
Inventor： Francine BEHAR-COHEN , Min ZHAO
IPC: C12Q1/6883 , A61K31/585
CPC classification number: C12Q1/6883 , A61K31/585 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
Abstract: Central Serous chorioretinopathy (CSCR) is primarily an ocular disease, affecting the choroid and the retinal pigment epithelium. To date, no systemic biomarker of CSCR have been discovered that could link both forms and help the diagnosis in challenging cases. In the present invention, the inventors measure in European cohorts of CSCR patients (n=168) with (n=90) or without epitheliopathy (n=78) and a cohort of 153 control subjects without any ocular disease history, the serum levels of NGAL and the NGAL/MMP9 complex. Serum NGAL (ng/ml) was significantly higher in the control group (108.8±46.8) than in the CSCR cohort (80.4±46.4, p
-
公开(公告)号：US20230142694A1
公开(公告)日：2023-05-11
申请号：US17935255
申请日：2022-09-26
Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) , UNIVERSITÉ PARIS CITÉ , SORBONNE UNIVERSITÉ
Inventor： Guido KROEMER , José Manuel BRAVO SAN PEDRO
CPC classification number: C07K16/18 , A61K39/0005
Abstract: Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets. Accordingly, the present invention relates to methods and pharmaceutical compositions for modulating autophagy based on the modulation of the activity or expression of DBI.
-
公开(公告)号：US11541131B2
公开(公告)日：2023-01-03
申请号：US16491623
申请日：2018-03-09
Applicant: GENETHON , UNIVERSITE D'EVRY VAL D'ESSONNE , INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , SORBONNE UNIVERSITÉ
Inventor： Federico Mingozzi , Giuseppe Ronzitti , Patrice Vidal
Abstract: The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.
-
公开(公告)号：US11534479B2
公开(公告)日：2022-12-27
申请号：US16965700
申请日：2019-02-18
Applicant: ILTOO PHARMA , ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS , SORBONNE UNIVERSITÉ
Inventor： David Klatzmann , Roberta Lorenzon , Michèle Rosenzwajg , Patrice Cacoub , Arsene Mekinian
Abstract: The invention relates to the use of interleukin-2 in treating Sjögren's syndrome in a subject, wherein IL-2 is to be administered at a low dose of less than about 3.5 MIU/day.
-
公开(公告)号：US11510936B2
公开(公告)日：2022-11-29
申请号：US16496738
申请日：2018-03-23
Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , SORBONNE UNIVERSITÉ , UNIVERSITAT DE BARCELONA
Inventor： Jean-Antoine Girault , Albert Giralt , Veronica Ines Brito , Silvia Gines
IPC: C07H21/04 , A61K31/713 , C12N9/12 , C12N15/86 , A61K48/00
Abstract: In the present invention it is shown that the inactivation of the Pyk2 gene does not alter hippocampal development but prevents hippocampal-dependent memory tasks and LTP. Inventors clearly provide evidence for multiple roles of Pyk2 in spine morphology and postsynaptic structure. Thus, the inventors used direct overexpression of PYK2 by AAV-mediated gene transfer into the brain of Huntington's and Alzheimer's mouse models and found that overexpression of PYK2 in these 2 models improves synaptic properties and spine density deficits which is also accompanied by a rescue of spatial memory. Accordingly it was demonstrated that PYK2 may restore cognitive functions in neurodegenerative diseases. Thus the present invention relates to methods and pharmaceutical compositions for the treatment of neurodegenerative disease. In particular the present invention relates to a method of treating neurodegenerative disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for PYK2 polypeptide.
-
-
-
-
-
-
-
-
-
Search Results
172
records
(took 0.036 seconds)
